cantargia.com
संपर्क करें
कम्पनी के बारे में
The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also been shown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia
SE
अनजान
सत्यापित कंपनी नहीं
व्यापार पारदर्शिता
- कंपनी की जानकारी सत्यापित नहीं की
- समीक्षा के लिए अपने ग्राहकों से पूछें
- नकारात्मक समीक्षाओं का जवाब नहीं दिया